D
DxCover
Developing a spectroscopic liquid biopsy for rapid detection of cancer
About DxCover
DxCover is a clinical-stage liquid biopsy company that has developed the PANAROMIC™ platform for early detection of multiple cancers. The company's technology, known as Multi-Omic Spectral Analysis (MOSA-Dx), analyzes the biochemical profile of a patient's blood serum using infrared spectroscopy and artificial intelligence to identify the presence or absence of disease.
Read full description
DxCover's platform is designed to provide rapid, cost-effective, and non-invasive cancer diagnostics. The company is currently conducting clinical trials for the detection of brain, colorectal, and lung cancers. By detecting cancers at an earlier stage, DxCover aims to improve patient outcomes and reduce healthcare costs. The company's business model is focused on the development and commercialization of its diagnostic tests for use in clinical settings, such as hospitals and laboratories.
At a glance
- Status
- Operational
- Founded
- 2016
- Headquarters
- Glasgow, United Kingdom
- Employees
- 30
- Open positions
- None listed
- Dealroom signal
- 72.0/100
- Industry
- Health
- Sub-industry
- BioTechnology, Medical Devices, Health Platform
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Neurology, Core AI, Health Diagnostics
- Technology
- Artificial Intelligence, Deep Tech, Recognition Technology
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | Feb 2025 | $6.6M | $50M | SIS Ventures · University of Strathclyde · Eos Advisory · Norcliffe Capital | ↗ |
| SERIES A✓Equity / VC | Feb 2023 | $9.9M | $40M | SIS Ventures · Mark Bamforth · Eos Advisory · Scottish Enterprise Growth Investments | ↗ |
Growth signals
Latest recorded traffic for DxCover is 820 monthly website visits, down 75.9% over the last three months. DxCover's team declined 6.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed7 investors entered at this stage
Scottish EDGE
Scottish Enterprise Growth Investments
Mercia Asset Management
Eos Advisory
SIS Ventures
Norcliffe Capital
Strathclyde University Incubator
Series A4 investors entered at this stage
Mark Bamforth
University of Strathclyde
Maven Capital Partners
Macmillan Cancer Support
Other known investors4 additional known investors
Tech Nation
Alba Equity
Investing Women
Mercia Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about DxCover on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See DxCover’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.